Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Antiretroviral Drugs
Pharma
Gilead's PrEP shows early promise in once-yearly dosing
Once-yearly lenacapavir achieved blood concentrations that exceeded those associated with the strong efficacy that its twice-yearly version showed.
Angus Liu
Mar 11, 2025 2:30pm
GSK's Dovato matches Gilead's Biktarvy with less weight gain
Jul 23, 2024 4:00am
WHO flags increasing resistance to GSK's Tivicay in 4 countries
Mar 6, 2024 2:02pm
GSK sees £7B in HIV sales by 2026, updates next-gen timelines
Sep 28, 2023 9:00am
Gilead's twice-yearly HIV med snags first nod after FDA rebuff
Aug 22, 2022 10:25am
Gilead trumpets a Biktarvy win in HIV, hepatitis B co-infection
Aug 1, 2022 10:17am
